Compass Therapeutics announces first-in-human Phase 1 trial of CTX-471
Category: #health  By Saipriya Iyer  Date: 2019-07-10
  • share
  • Twitter
  • Facebook
  • LinkedIn

Compass Therapeutics announces first-in-human Phase 1 trial of CTX-471

CTX-471 has shown promising preclinical data, which include total eradication of established tumors in syngeneic mouse models.

Compass Therapeutics, a clinical-stage biopharmaceutical firm targeting human immune synapse with novel monoclonal and multi-specific antibody therapeutics, has recently announced the commencement of its first-in-human, open-label, multi-center Phase 1 trial of CTX-471.

For the uninitiated, CTX-471 is a fully human monoclonal antibody that binds and triggers a unique epitope of the co-stimulatory receptor CD137 expressed on NK cells and T cells.

Sources close to the pilot claim that patient enrollment in the trial is open to subjects with metastatic or locally advanced solid cancers that are developed while receiving an approved PD-L1 or PD-1 inhibitor for a minimum period of three months.

F. Stephen Hodi, MD, Director of the Melanoma Center, The Center for Immuno-Oncology at Dana-Farber/Brigham, and Women’s Cancer Center, said that the field of oncology is in immense need for novel ways that enable the immune system to fight cancer beyond PD-1/PD-L1 checkpoint inhibitors. He said they currently own very limited options to treat patients in whom PD-L1 or PD-1 inhibitors has failed.

Source cite that the multiple ascending dose (MAD) study has the potential for a dose expansion phase. The primary objective of MAD study is to assess the tolerability and safety of CTX-471 monotherapy at various doses.

The dose expansion stage will evaluate a larger cohort of patients to determine an optimized dose for future Phase 2 studies. Moreover, the secondary endpoints will include measures of overall response rate and progression- free survival, among others.

Speaking on the trial, Thomas Schuetz, MD, PhD, Scientific founder & CEO, Compass Therapeutics, said the company is delighted to have reached this milestone to begin testing its treatment on patients.

He said that their firm expects CTX-471 to be a best-in-class CD137 agonist due to its promising preclinical data, which include total eradication of established tumors in syngeneic mouse models and development of long-term, functional immunological memory in these models.

Source Credit: https://www.compasstherapeutics.com/press-releases/compass-therapeutics-announces-first-patient-dosed-in-phase-1-trial-of-ctx-471/



About Author

Saipriya Iyer

Email: [email protected]   

Saipriya Iyer

Saipriya Iyer develops content for Market Size Forecasters, Algosonline, and myriad other platforms. A computer engineer by profession, she ventured into the field of writing for the love of playing with words. Having had a previous experience of 3 years under her bel...

Read More

More News By Saipriya Iyer

Triple Gene releases Phase 1 study data for INXN-4001 in heart failure
Triple Gene releases Phase 1 study data for INXN-4001 in heart failure
By Saipriya Iyer

Triple Gene LLC- a U.S. based cardiovascular gene therapy enterprise recently furnished preliminary data from its Phase 1 trial of INXN-4001, an investigational therapeutic candidate used in the treatment of cardiac fa...

Alibaba plans to offer bitcoin rewards to shoppers through Lolli
Alibaba plans to offer bitcoin rewards to shoppers through Lolli
By Saipriya Iyer

 

  • Now Alibaba shoppers can earn free bitcoin when they purchase products on Alibaba's e-commerce platform
  • Reportedly, the partnership would enable shoppers...

Daiichi Sankyo announces positive results from Phase 3 pivotal trial
Daiichi Sankyo announces positive results from Phase 3 pivotal trial
By Saipriya Iyer

Daiichi Sankyo Company, Limited (hereafter Daiichi Sankyo), today made a breakthrough announcement stating that the main objective has been achieved from ESAX-DN—a phase 3 pivotal study of esaxerenone—a pro...